{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:06:24Z","timestamp":1772165184120,"version":"3.50.1"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>A twice-daily single inhaler triple therapy consisting of budesonide\/glycopyrrolate\/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective of this AURA study is to describe patient characteristics, exacerbation and treatment history, and healthcare resource utilization (HCRU) before BGF initiation to better inform treatment decisions for prescribers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study leveraged data of all payer types from IQVIA\u2019s Longitudinal Prescription Data (LRx) linked to Medical Data (Dx). Patients with COPD who had \u2a7e1 LRx claim for BGF between 1 October 2020 and 30 September 2021 were included. The date of first BGF claim was the index date. Patient demographic and clinical characteristics, history of COPD exacerbation or related event, treatment history, and HCRU were assessed during the 12 months before index (baseline).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 30,339 patients with COPD initiating BGF (mean age: 68.2 years; 57.1% female; 67.6% Medicare). Unspecified COPD (J44.9; 74.0%) was the most commonly coded COPD phenotype. The most prevalent respiratory conditions\/symptoms were dyspnea (50.8%), lower respiratory tract infection (25.3%), and sleep apnea (19.0%). Uncomplicated hypertension (58.8%), dyslipidemia (43.9%), cardiovascular disease (41.4%), and heart failure (19.9%) were the most prevalent nonrespiratory conditions. During the 12-month baseline, 57.9% of patients had evidence of a COPD exacerbation or related event, and 14.9% had \u2a7e1 COPD-related emergency department (ED) visit; 21.0% of patients had evidence of prior triple therapy use, while 54.3% had \u2a7e1 oral corticosteroid (OCS) fill. Among OCS users, 29.9% had cumulative exposures &gt;1000 mg [median [Q1\u2013Q3] exposure: 520 (260\u20131183) mg].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This real-world data analysis indicates that BGF is being initiated in patients with COPD experiencing symptoms and exacerbations despite current therapy, and among patients who have various chronic comorbidities, most often cardiopulmonary-related.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666231164534","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T03:09:13Z","timestamp":1680577753000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics of initiators of budesonide\/glycopyrrolate\/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study"],"prefix":"10.1177","volume":"17","author":[{"given":"Edward C.","family":"Portillo","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Wisconsin, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pollack","sequence":"additional","affiliation":[{"name":"US Medical, BioPharmaceuticals, AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"IQVIA, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kainan","family":"Sun","sequence":"additional","affiliation":[{"name":"IQVIA, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-6587","authenticated-orcid":false,"given":"Xiaohui","family":"Zhao","sequence":"additional","affiliation":[{"name":"IQVIA, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Kruse","sequence":"additional","affiliation":[{"name":"US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Feigler","sequence":"additional","affiliation":[{"name":"US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Patel","sequence":"additional","affiliation":[{"name":"US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee M.","family":"Near","sequence":"additional","affiliation":[{"name":"IQVIA, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"bibr1-17534666231164534","unstructured":"Global Initiative for Chronic Obstructive Pulmonary Disease. Global initiative for chronic obstructive lung disease 2023 report, 2023, https:\/\/goldcopd.org\/2023-gold-report-2\/"},{"key":"bibr2-17534666231164534","volume-title":"Mortality in the United States, 2020. NCHS data brief, no 427","author":"Murphy SL","year":"2021"},{"key":"bibr3-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.255"},{"key":"bibr4-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00002610"},{"key":"bibr5-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201606-1162PP"},{"key":"bibr6-17534666231164534","unstructured":"Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2022 report, 2022, https:\/\/goldcopd.org\/2022-gold-reports\/"},{"key":"bibr7-17534666231164534","unstructured":"Approval package for application number: 209482Orig1s000, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209482Orig1s000Approv.pdf (2017, accessed 21 September 2022)."},{"key":"bibr8-17534666231164534","unstructured":"Approval letter for NDA 212122, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/212122Orig1s000ltr.pdf (2020, accessed 21 September 2022)."},{"key":"bibr9-17534666231164534","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S234823"},{"key":"bibr10-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.04.005"},{"key":"bibr11-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.07.009"},{"key":"bibr12-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-022-00189-6"},{"key":"bibr13-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152242"},{"key":"bibr14-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2606"},{"key":"bibr15-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31819432e5"},{"key":"bibr16-17534666231164534","first-page":"205","volume":"25","author":"Wallace AE","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr17-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151357"},{"key":"bibr18-17534666231164534","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S238408"},{"key":"bibr19-17534666231164534","unstructured":"Cole B. The impact of the COVID-19 pandemic on access to health care. Health Policy Brief, 2020, https:\/\/www.nasi.org\/research\/medicare-health-policy\/the-impact-of-the-covid-19-pandemic-on-access-to-health-care\/"},{"key":"bibr20-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25578"},{"key":"bibr21-17534666231164534","unstructured":"Samson LW, Tarazi W, Turrini G, et al. Medicare beneficiaries\u2019 use of telehealth in 2020: trends by beneficiary characteristics and location, 2021, https:\/\/aspe.hhs.gov\/reports\/medicare-beneficiaries-use-telehealth-2020"},{"key":"bibr22-17534666231164534","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S51012"},{"key":"bibr23-17534666231164534","volume":"357","author":"Waljee AK","year":"2017","journal-title":"BMJ"},{"key":"bibr24-17534666231164534","volume":"3","author":"Walters JA","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr25-17534666231164534","volume":"3","author":"Walters JA","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr26-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.06.007"},{"key":"bibr27-17534666231164534","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S35711"},{"key":"bibr28-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00244-5"},{"key":"bibr29-17534666231164534","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081058"},{"key":"bibr30-17534666231164534","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4918"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666231164534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666231164534","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666231164534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:12:40Z","timestamp":1741025560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666231164534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"alternative-id":["10.1177\/17534666231164534"],"URL":"https:\/\/doi.org\/10.1177\/17534666231164534","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666231164534\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17534666231164534"}}